Day One Biopharmaceuticals (DAWN) Competitors $13.31 -1.01 (-7.05%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DAWN vs. ARQT, MNKD, CSTL, LMAT, SGMO, BPMC, NUVL, LNTH, KRYS, and ACLXShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Arcutis Biotherapeutics (ARQT), MannKind (MNKD), Castle Biosciences (CSTL), LeMaitre Vascular (LMAT), Sangamo Therapeutics (SGMO), Blueprint Medicines (BPMC), Nuvalent (NUVL), Lantheus (LNTH), Krystal Biotech (KRYS), and Arcellx (ACLX). These companies are all part of the "medical" sector. Day One Biopharmaceuticals vs. Arcutis Biotherapeutics MannKind Castle Biosciences LeMaitre Vascular Sangamo Therapeutics Blueprint Medicines Nuvalent Lantheus Krystal Biotech Arcellx Day One Biopharmaceuticals (NASDAQ:DAWN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Which has better earnings and valuation, DAWN or ARQT? Day One Biopharmaceuticals has higher earnings, but lower revenue than Arcutis Biotherapeutics. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One BiopharmaceuticalsN/AN/A-$188.92M-$1.03-12.92Arcutis Biotherapeutics$59.61M18.18-$262.14M-$1.79-5.17 Which has more volatility & risk, DAWN or ARQT? Day One Biopharmaceuticals has a beta of -1.51, indicating that its share price is 251% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Does the media prefer DAWN or ARQT? In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 6 mentions for Day One Biopharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 1.02 beat Day One Biopharmaceuticals' score of 0.61 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate DAWN or ARQT? Day One Biopharmaceuticals presently has a consensus target price of $35.71, indicating a potential upside of 168.33%. Arcutis Biotherapeutics has a consensus target price of $15.50, indicating a potential upside of 67.39%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Day One Biopharmaceuticals is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is DAWN or ARQT more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Day One Biopharmaceuticals' return on equity of -22.40% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Does the MarketBeat Community prefer DAWN or ARQT? Arcutis Biotherapeutics received 14 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. However, 66.18% of users gave Day One Biopharmaceuticals an outperform vote while only 64.13% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes4566.18% Underperform Votes2333.82% Arcutis BiotherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% Do insiders and institutionals hold more shares of DAWN or ARQT? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryDay One Biopharmaceuticals beats Arcutis Biotherapeutics on 11 of the 18 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-12.924.7865.5913.48Price / SalesN/A377.381,278.7587.67Price / CashN/A51.2039.7035.24Price / Book2.429.686.475.93Net Income-$188.92M$154.43M$119.73M$225.73M7 Day Performance-18.79%-9.46%-5.13%-1.34%1 Month Performance-11.74%-7.27%-2.71%1.15%1 Year Performance9.64%28.13%31.08%24.02% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals1.7914 of 5 stars$13.31-7.1%$35.71+168.3%+13.6%$1.34BN/A-12.9260Insider SellingShort Interest ↑ARQTArcutis Biotherapeutics2.0891 of 5 stars$10.84+0.2%N/A+374.9%$1.27B$59.61M-6.06150Positive NewsMNKDMannKind3.6886 of 5 stars$7.22-1.6%N/A+88.9%$1.99B$198.96M103.14400CSTLCastle Biosciences3.5758 of 5 stars$33.78+1.5%N/A+46.0%$946.18M$219.79M168.91540Short Interest ↓LMATLeMaitre Vascular3.6393 of 5 stars$105.50+1.2%N/A+92.6%$2.37B$193.48M57.65614Short Interest ↓Positive NewsSGMOSangamo Therapeutics2.4765 of 5 stars$2.70-5.9%N/A+484.5%$562.20M$12.28M-1.96480Earnings ReportAnalyst ForecastAnalyst RevisionBPMCBlueprint Medicines3.0865 of 5 stars$99.87-1.0%N/A+41.6%$6.34B$249.38M-47.33640Analyst ForecastShort Interest ↑News CoverageNUVLNuvalent3.1126 of 5 stars$94.39-1.1%N/A+49.7%$6.12BN/A-33.9540Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLNTHLantheus4.6106 of 5 stars$84.08-3.9%N/A+12.7%$5.85B$1.30B13.99834Gap DownHigh Trading VolumeKRYSKrystal Biotech4.7252 of 5 stars$195.87-1.9%N/A+73.6%$5.63B$50.70M110.66229ACLXArcellx2.8644 of 5 stars$106.53+3.4%N/A+68.4%$5.54B$110.32M-150.04130Analyst ForecastInsider SellingShort Interest ↓ Related Companies and Tools Related Companies Arcutis Biotherapeutics Competitors MannKind Competitors Castle Biosciences Competitors LeMaitre Vascular Competitors Sangamo Therapeutics Competitors Blueprint Medicines Competitors Nuvalent Competitors Lantheus Competitors Krystal Biotech Competitors Arcellx Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DAWN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DAWN Stock Alerts